You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Scientists claim to have developed 'ultrapotent' Covid-19 vaccine candidate

Scientists have developed a vaccine candidate for Covid that produces "extremely high levels" of protective antibodies in animal models, an advance that may lead to a therapeutic to curb the pandemic

Coronavirus Vaccine | Scientists | Coronavirus

Press Trust of India  |  Washington 

Coronavirus, vaccine, covid, drugs, clinical trials

have developed a vaccine candidate for COVID-19 that produces "extremely high levels" of protective antibodies in animal models, an advance that may lead to a novel therapeutic to curb the pandemic.

According to the researchers, including those from the University of Washington (UW) School of Medicine in the US, the nanoparticle vaccine produces virus-neutralising antibodies in mice at levels much greater than is seen in people who have recovered from the disease.

The study, published in the journal Cell, noted that it generates ten times more neutralising antibodies in mice, even at a six-fold lower vaccine dose, and also shows a strong B-cell immune response after administration, which can be critical for a durable vaccine effect.

When a single nonhuman primate was immunised with the vaccine, the said the candidate therapeutic produced neutralising antibodies targeting multiple different sites on the spike protein of the coronavirus, which it uses to enter human cells.

They said this may ensure protection against mutated strains of the virus, should they arise.

According to the study, the molecular structure of the vaccine roughly mimics that of a virus, which may account for its enhanced ability to provoke an immune response.

"We hope that our nanoparticle platform may help fight this pandemic that is causing so much damage to our world," said Neil King, a co-author of the study from UW Medicine.

"The potency, stability, and manufacturability of this vaccine candidate differentiate it from many others under investigation," King said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, November 03 2020. 17:57 IST